CAUTION: We have been advised that fraudulent emails with a modified domain name have been sent by a source purporting to be from Aird & Berlis LLP. These communications are not legitimate and are not from Aird & Berlis LLP. Disregard any such emails and do not engage with the sender or the email in any way. Please report the attempted fraud by contacting the Canadian Anti-Fraud Centre and by emailing Aird & Berlis LLP at help@airdberlis.com.

Back to all Representative Matters
Feb 19, 2021

PsyBio Completes Reverse Takeover and $14.5 Million Private Placement

Sherri M. Altshuler, Melanie Cole, Adria Leung Lim, Amy Marcen-Gaudaur, Russell J. Sanders, Meredith McCann, David Mba and Barbara Worndl

PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) (“PsyBio”) recently completed a reverse takeover (the “Reverse Takeover”) of PsyBio Therapeutics, Inc. (the “Target”), a biotechnology company developing a new class of drugs intended for the potential treatment of mental health challenges and other disorders.

The Reverse Takeover was completed by way of a “three-cornered” amalgamation pursuant to the provisions of the Business Corporations Act (British Columbia) and a “three-cornered” merger under the laws of the State of Delaware. The Reverse Takeover constitutes PsyBio’s Qualifying Transaction (as defined by Policy 2.4 of the TSX Venture Exchange (the “TSXV”).

In connection with the Reverse Takeover, on December 4, 2020, PsyBio Therapeutics Financing Inc. (“Finco”), a special purpose financing entity, completed a brokered private placement of 41,409,698 subscription receipts (“Subscription Receipts”) at a price of $0.35 per Subscription Receipt for aggregate gross proceeds of approximately $14.5 million. The Subscription Receipts were converted into shares of Finco and exchanged for subordinate voting shares of PsyBio (“Subordinate Voting Shares”) on closing of the Reverse Takeover.

The Subordinate Voting Shares commenced trading on the TSXV under the symbol “PSYB” on February 25, 2021.  

Aird & Berlis represented the Target with a team that included Sherri Altshuler, Melanie Cole, Adria Leung Lim, Amy Marcen-Gaudaur, Russell Sanders, Meredith McCann, David Mba (Corporate and Securities) and Barbara Worndl (Tax).

Related Industries

Related Representative Matters

Representative Matters
Maritime Resources Completes $6.9 Million Brokered Private Placement Jeffrey K. Merk, Marek Lorenc, Liam Tracey-Raymont, David Mba and Carol J. Burns Mar 22, 2021 Aird & Berlis represented Maritime Resources Corp., a Canadian gold mining and exploration compan... Aird & Berlis represented Maritime Resources Corp., a Canadian gold mining and exploration company, in a brokered private placement of common shares on a “flow-through” basis for approximately $6.9 million.
Representative Matters
MediPharm Labs Closes $33 Million Bought Deal Equity Financing Melanie Cole, Amy Marcen-Gaudaur, Meredith McCann and Barbara Worndl Mar 09, 2021 Aird & Berlis LLP advised MediPharm Labs Corp. in connection with its bought deal offering of uni... Aird & Berlis LLP advised MediPharm Labs Corp. in connection with its bought deal offering of units for total gross proceeds of $33,350,000.
Representative Matters
Cybin Completes $34 Million Bought Deal Offering Sherri M. Altshuler, Melanie Cole, Danny Kharazmi, Russell J. Sanders, Sean Green, Meredith McCann and Barbara Worndl Feb 04, 2021 Aird & Berlis acted for Cybin Inc., a biotechnology company focused on progressing psychedelic th... Aird & Berlis acted for Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, in a bought deal short form prospectus offering.